# Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

> **NCT07476001** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 12 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Testosterone cypionate (Tc)
- **DRUG:** ADT with Luteinizing hormone-releasing hormone (LHRH) analog
- **DRUG:** PSMA-617

## Key facts

- **NCT ID:** NCT07476001
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476001, "Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT07476001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*